SQZ Biotechnologies (SQZ) Stock Price, News & Analysis

Company Overview

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $0.03 to $0.03
• 50-Day Range: $0.02 to $0.03
• 52-Week Range: $0.25 to $3.56
• Volume: 6,904 shs
• Average Volume: 455,220 shs
• Market Capitalization: $737,275.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SQZ Stock Analysis - Frequently Asked Questions

How have SQZ shares performed this year?

SQZ Biotechnologies' stock was trading at $0.0199 at the beginning of 2024. Since then, SQZ shares have increased by 25.6% and is now trading at $0.0250.
View the best growth stocks for 2024 here.

How were SQZ Biotechnologies' earnings last quarter?

SQZ Biotechnologies (NYSE:SQZ) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($8.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.60) by $2.40. The firm had revenue of $4.76 million for the quarter, compared to the consensus estimate of $11.64 million. SQZ Biotechnologies had a negative net margin of 369.96% and a negative trailing twelve-month return on equity of 119.83%.

When did SQZ Biotechnologies' stock split?

Shares of SQZ Biotechnologies reverse split on the morning of Friday, July 7th 2023. The 1-10 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did SQZ Biotechnologies IPO?

SQZ Biotechnologies (SQZ) raised $75 million in an initial public offering (IPO) on Friday, October 30th 2020. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. BofA Securities and Stifel served as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of SQZ Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SQZ Biotechnologies investors own include Minerva Neurosciences (NERV), Illumina (ILMN), NVIDIA (NVDA), Oramed Pharmaceuticals (ORMP), Absci (ABSI), Allogene Therapeutics (ALLO) and Beam Therapeutics (BEAM).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Transportation
• Current Symbol: NYSE:SQZ
• CUSIP: N/A
• CIK: 1604477
• Web: www.sqzbiotech.com
• Phone: 617-758-8672
• Fax: N/A
• Employees: 1,620
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-79,460,000.00
• Net Margins: -369.96%
• Pretax Margin: -408.99%
• Return on Equity: -119.83%
• Return on Assets: -59.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.50
• Quick Ratio: 3.50

Sales & Book Value

• Annual Sales: $18.16 million
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 29,491,000
• Free Float: 24,772,000
• Market Cap: $737,275.00
• Optionable: Not Optionable
• Beta: 2.34